Description
Celsion Corporation is a clinical stage biotechnology company. The Company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer and ThermoDox, a heat-activated liposomal encapsulation of doxorubicin for several cancer indications. Its GEN-1, an IL-12 DNA plasmid vector formed into nanoparticles with a lipopolymeric delivery system, is the product candidate designed via the TheraPlas platform technology.
Its Lysolipid Thermally Sensitive Liposomes (LTSL) technology is a heat-sensitive liposomal formulation that targets disease with therapeutics in the presence of mild heat. Its TheraSilence technology delivers synthetically generated inhibitory RNA (RNAi) to regulate protein expression in target cells.
